Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
July 25 2024 - 8:00AM
Women’s health innovator Evofem Biosciences, Inc. (“Evofem” or “the
Company”) (OTCQB: EVFM) today announced that Saundra Pelletier,
Chief Executive Officer and Amy Raskopf, Chief Business
Development Officer, will present and host one-on-one meetings at
the OTCQB Venture Virtual Investor Conference as follows:
Date: |
Thursday, August 1, 2024 |
Time: |
10:30am ET |
Access Webcast:(live and archive) |
https://bit.ly/3LySuJNor archive:
https://evofem.investorroom.com/events |
During this live, interactive online event,
investors are invited to ask the Company questions in real-time. It
is recommended that investors pre-register and run the online
system check to expedite participation and receive event
updates.
Recent Company Highlights
- Acquired global
rights to SOLOSEC® (secnidazole) 2 g oral granules, a single-dose
oral antibiotic to treat bacterial vaginosis and trichomoniasis,
two common sexual health infections.
- Licensed
commercial rights to hormone-free Phexxi® (lactic acid, citric acid
and potassium bitartrate) contraceptive gel in the Middle East to
Emirati pharmaceutical company Pharma 1 Drug Store.
- Partnered with
leading telemedicine company Hello Alpha to add Phexxi to its
commercial offering as a hormone-free contraception solution for
women, especially those on GLP-1s and others looking for
hormone-free birth control.
Learn more about the event at
www.virtualinvestorconferences.com.
About Evofem BiosciencesEvofem
Biosciences, Inc., is commercializing innovative products to
address unmet needs in women's sexual and reproductive health. The
Company's first FDA-approved product, Phexxi® (lactic acid,
citric acid and potassium bitartrate), is a hormone-free,
on-demand prescription contraceptive vaginal gel. It comes in a box
of 12 pre-filled applicators and is applied 0-60 minutes before
each act of sex.
In July 2024 Evofem broadened its commercial
offering with the acquisition of SOLOSEC® (secnidazole) 2g oral
granules, an FDA-approved oral antibiotic for the treatment of
two sexual health diseases: bacterial vaginosis (BV), a common
vaginal infection, in females 12 years of age and older, and
trichomoniasis, a common sexually transmitted infection (STI), in
people 12 years of age and older. SOLOSEC provides a complete
course of therapy in just one dose.
In December 2023, Evofem entered into a
Merger Agreement with Aditxt, Inc. (Nasdaq: ADTX) under
which Aditxt intends to acquire Evofem. The parties reinstated and
amended the Merger Agreement, as amended, in May and July
2024, and are working to close the contemplated transaction in the
second half of 2024.
Follow us on:LinkedIn:
https://www.linkedin.com/company/evofemFacebook:
http://www.facebook.com/EvofemX (f/k/a Twitter):
https://x.com/Evofem
Phexxi® and SOLOSEC® are registered trademarks of Evofem
Biosciences, Inc.
Forward-Looking StatementsThis
press release includes "forward-looking statements" within the
meaning of the safe harbor for forward-looking statements provided
by Section 21E of the Securities Exchange Act of 1934, as amended,
and the Private Securities Litigation Reform Act of 1995 including,
without limitation, the likelihood of success and anticipated
timing to close the contemplated Aditxt transaction. You are
cautioned not to place undue reliance on these forward-looking
statements, which are current only as of the date of this press
release. Each of these forward-looking statements involves risks
and uncertainties. Important factors that could cause actual
results to differ materially from those discussed or implied in the
forward-looking statements are disclosed in the Company's SEC
filings, including its Annual Report on Form 10-K for the year
ended December 31, 2023 filed with the SEC on March
27, 2024, Quarterly Report on Form 10-Q for the three months
ended March 31, 2024 filed with the SEC on May 12,
2024, and any subsequent filings. All forward-looking statements
are expressly qualified in their entirety by such factors. The
Company does not undertake any duty to update any forward-looking
statement except as required by law.
Contact
Amy Raskopf
Evofem Biosciences, Inc.
ir@evofem.com
(917) 673-5775
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jul 2023 to Jul 2024